Shire paying $5.2bn for rare disease specialist NPS
This article was originally published in Scrip
Executive Summary
Shire will put its $1.6bn cash breakup fee from AbbVie – and then some – to use via the Dublin-based company's $5.2bn acquisition of NPS Pharmaceuticals.
You may also be interested in...
Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead
Shire’s Perry Sternberg and Phil Vickers are optimistic about recent launches and products in late stages of development in key rare disease and specialty therapeutic areas, many of which come from Baxalta and other high-profile acquisitions.
Shire's Ornskov: The Modest Pediatrician With Fierce Corporate Ambition
Since becoming CEO of Shire in April 2013, Flemming Ornskov has overseen around $50bn in M&A deals. He steered the company through the ultimately abortive takeover by AbbVie and walked away with a break fee of $1.6bn, going on to consummate instead Shire’s $32bn acquisition of Baxalta earlier this year. He spoke to Scrip about his vision and values.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.